文献速递肿瘤 PET/CT核素与放射性配体治疗

18F-DCFPyL PET/CT检测双极雄激素治疗中转移性去势抵抗性前列腺癌的早期进展

Detection of Early Progression with 18F-DCFPyL PET/CT in Men with Metastatic Castration-Resistant Prostate Cancer Receiving Bipolar Androgen Therapy.
PubMed 文献 · J Nucl Med · 2021-01-15

该研究分析6例接受双极雄激素治疗(BAT)的转移性去势抵抗性前列腺癌(mCRPC)患者,在基线和治疗3个月后行18F-DCFPyL PET/CT。6例中3例(50%)PET/CT示进展,同期常规影像为稳定或更好,且均在PET/CT进展后3个月内出现CT或骨扫描的影像学进展;另3例PET/CT无进展者至少6个月内未观察到影像学进展。

要点

  • 18F-DCFPyL PET/CT可在常规影像稳定时检出mCRPC患者BAT治疗后的早期进展。
  • PET/CT进展后3个月内出现CT或骨扫描的影像学进展。
  • PET/CT无进展者至少6个月内未出现影像学进展。

核心结论

  • 接受BAT的mCRPC患者中,18F-DCFPyL PET/CT出现新的放射性示踪剂摄取病灶可提示早期进展。

研究设计与样本

  • 研究纳入6例接受BAT的mCRPC患者,在基线和治疗3个月后行18F-DCFPyL PET/CT。

主要发现

  • 6例中3例(50%)在18F-DCFPyL PET/CT上出现进展,定义为出现任何新的18F-DCFPyL摄取病灶。
  • 3例PET/CT进展者同期常规影像均为稳定疾病或更好。
  • PET/CT进展后3个月内观察到CT或骨扫描的影像学进展。
  • 3例PET/CT无进展者至少6个月内未观察到影像学进展。

关键数值与推荐

  • PSMA靶向PET/CT进展定义为出现任何新的18F-DCFPyL摄取病灶。

临床怎么用

  • 对接受BAT的mCRPC患者,18F-DCFPyL PET/CT可用于在常规影像稳定时提示早期进展。

局限性

  • 研究样本量仅6例,结论需更大样本验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Bipolar androgen therapy (BAT) is an emerging treatment for metastatic castration-resistant prostate cancer (mCRPC). 18F-DCFPyL is a small-molecule PET radiotracer targeting prostate-specific membrane antigen (PSMA). We analyzed the utility of 18F-DCFPyL PET/CT in determining clinical response to BAT. Methods: Six men with mCRPC receiving BAT were imaged with 18F-DCFPyL PET/CT at baseline and after 3 mo of treatment. Progression by PSMA-targeted PET/CT was defined as the appearance of any new 18F-DCFPyL-avid lesion. Results: Three of 6 (50%) patients had progression on 18F-DCFPyL PET/CT. All 3 had stable disease or better on contemporaneous conventional imaging. Radiographic progression on CT or bone scanning was observed within 3 mo of progression on 18F-DCFPyL PET/CT. For the 3 patients who did not have progression on 18F-DCFPyL PET/CT, radiographic progression was not observed for at least 6 mo. Conclusion: New radiotracer-avid lesions on 18F-DCFPyL PET/CT in men with mCRPC undergoing BAT can indicate early progression.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Markowski MC, Velho PI, Eisenberger MA, et al. Detection of Early Progression with 18F-DCFPyL PET/CT in Men with Metastatic Castration-Resistant Prostate Cancer Receiving Bipolar Androgen Therapy. J Nucl Med. 2021. PMID: 33452039. doi:10.2967/jnumed.120.259226

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。